Tag Archives: biology
UGA iGEM team wins gold at international synthetic biology competition
The 2015 UGA iGEM team included 16 undergraduates from the Franklin College of Arts and Sciences and the College of Engineering, led by Rebecca Buchanan, studying biochemistry and molecular biology. Undergraduates attending the jamboree were …
Read more on UGA Today
St. Laurent GS remembered for life of curiosity
Yiannis Savva, a postdoctoral research associate in molecular biology, cell biology and biochemistry, collaborated on ideas and published four reviews with St. Laurent. “I will remember when he first started here, his dream was to identify every RNA …
Read more on The Brown Daily Herald
Vaccine technology developed at Johns Hopkins could lead to treatment for …
The LAMP-vax platform—seen as a breakthrough technology for improving DNA vaccines—uses the body's natural biochemistry to develop a complete immune response. Through the new agreement, Tokyo-based Astellas Pharma has acquired an exclusive …
Read more on The Hub at Johns Hopkins
Lynchburg, Va. (PRWEB) May 15, 2015
Researchers from Liberty University’s Department of Biology & Chemistry have released the university’s first draft genome sequence, mapping the DNA of a popular strain of E. coli bacteria in hopes of helping to find a cure for diseases caused by the strain.
Though the Citrobacter rodentium (C. rodentium) strain DBS100 has been studied extensively, it had not previously been sequenced. The work will not only help Liberty’s research but also that of other prominent researchers for years to come.
“Publishing a draft genome will certainly raise the profile of Liberty University in regards to the kind of research we are doing,” said Dr. David DeWitt, chair of the Department of Biology & Chemistry. “A study like this really highlights the research involvement students can have with our faculty members.”
The genome sequencing was conducted by Dr. Andrew Fabich, associate professor of microbiology, and Abigail Lenz (’14), a biomedical science graduate assistant currently seeking her Master of Science in Biomedical Sciences, and in collaboration with Dr. Jeffery Tomkins, an adjunct Liberty professor.
The gene sequence, which is represented as a series of letters (A, for the nucleotide adenine; G, for guanine; T, for thymine; and C, for cytosine), is 5,385,810 characters long — over 800 pages when printed front and back in eight-point text.
Liberty purchased a DNA sequencer in 2013, adding to a growing arsenal of top-notch research equipment, which will be housed in the new Science Hall. Fabich said that sequencing genomes is quite common among leading scientific research institutions, so it is significant that Liberty invested in technology that will allow students to participate in top-quality research projects.
“We are doing cutting-edge research (that is) published in secular, scientific journals,” Fabich said. “Our students get hands-on training using the latest, greatest technology that is the most sophisticated, state-of-the-art equipment you find at major institutions.”
He added that the particular strain that Liberty sequenced as its first genome is significant because it is one of the most popular strains of Escherichia coli (E. coli) used in research. Fabich and many of his students, like Lenz, have been researching the strain because it is a model for enterohemorrhagic E. coli(EHEC), the leading cause of infectious kidney failure worldwide. C. rodentium is used in mice to mimic the effects EHEC produces in humans. Part of Lenz’s research involves genetic manipulations of the bacteria to help determine exactly how it infects the gastrointestinal tract.
Fabich’s research students have garnered awards and recognition for their work, including at the Virginia Academy of Science and the Undergraduate Research Symposium in the Chemical and Biological Sciences, and the American Society for Microbiology’s annual meeting.
The goal of this research is to help determine what triggers the change from good E. coli bacteria (helpful microbes are abundant in the human body) to infectious ones and ultimately lead to a cure for diseases caused by EHEC. Fabich is collaborating with Dr. Anthony Bauer, an associate professor in the Liberty University College of Osteopathic Medicine, on a grant proposal to develop a cure for EHEC.
Lenz, who earned her bachelor’s degree from Liberty in biochemistry and molecular biology with a minor in mathematics, did much of the research for the genome sequence and was the first author for the article, demonstrating Liberty’s commitment to training students to excel in their chosen field.
“I felt like she had a sense of ownership and that’s given her that sense of independence that you expect out of graduate students,” Fabich said.
Lenz said the research required long nights in the lab, enduring many failures to obtain desired results, but she is grateful for the opportunity.
“God’s guidance, timing, and wisdom are evident in every part of my research,” Lenz said. “God provided a sequencer shortly after I began my research, which has opened many doors for me. The people that I have worked with in lab (both professors and other researchers) have provided me with continual encouragement. I feel a great sense of purpose when working in the lab, knowing that I am gaining a deeper knowledge of the beautiful intricacy of God’s creation and working toward a better world for those suffering from EHEC infection.”
The draft genome is available in an online public database.
About Liberty University
Liberty University, founded in 1971, is the largest private, nonprofit university in the nation, the largest university in Virginia, and the largest Christian university in the world. Located near the Blue Ridge Mountains on more than 7,000 acres in Lynchburg, Va., Liberty offers more than 450 unique programs of study from the associate to the doctoral level. More than 200 programs are offered online. Liberty’s mission is to train Champions for Christ with the values, knowledge, and skills essential for impacting tomorrow’s world.
[wprebay kw=”biochemistry+2014″ num=”6″ ebcat=”-1″]
[wprebay kw=”biochemistry+2014″ num=”7″ ebcat=”-1″]
[wprebay kw=”biochemistry+2014″ num=”8″ ebcat=”-1″]
To purchase this program please visit http://www.greatpacificmedia.com/ Segment from the program DNA, RNA, and Protein Synthesis: Information to Structure. DVD Description Our DNA DVD…
Video Rating: 4 / 5
UNMC Researcher Part of Study in Nature Cell Biology
“The focus of my laboratory is on understanding the trafficking or movement of proteins from point to point within the cell,” said Dr. Caplan said, professor, biochemistry and molecular biology. “We have extensively studied and characterized a family …
Read more on WOWT
Penn State's Medvedev receives National Science Foundation CAREER award
Paul Medvedev, an assistant professor in the department of computer science and engineering, the department of biochemistry and molecular biology and the Genome Sciences Institute at the Huck at Penn State, has received a five-year National Science …
Read more on Penn State News
University researchers make breakthrough in lung cancer research
Marty W. Mayo, one of the researchers on the team and a biochemistry and molecular genetics associate professor, said this led them to believe the metastatic cells were leaving behind proteins which interacted with naïve cells. “Ultimately we …
Read more on University of Virginia The Cavalier Daily
[wprebay kw=”biochemistry+research” num=”3″ ebcat=”-1″]
[wprebay kw=”biochemistry+research” num=”4″ ebcat=”-1″]
[wprebay kw=”biochemistry+research” num=”5″ ebcat=”-1″]
Nutrition 21, LLC Announces The Presentation Of Results Of A Nitrosigine Clinical Study At The Renowned Experimental Biology 2014 Annual Meeting
Purchase, NY (PRWEB) May 05, 2014
Nutrition 21, LLC (“Nutrition 21”) is proud to announce the presentation of a new clinical study supporting Nitrosigine™ inositol-stabilized arginine silicate, titled, “A Clinical Evaluation to Determine the Safety, Pharmacokinetics and Pharmacodynamics of an Inositol-Stabilized Arginine Silicate Dietary Supplement in Healthy Adult Males.” The study will be presented today to scientists and other professionals at the acclaimed Experimental Biology 2014 annual meeting’s poster session and will be published in the FASEB (Federation of American Societies for Experimental Biology) Journal.
The clinical study demonstrated significant increases in plasma arginine levels (P<0.01) and serum silicon levels (P<0.01) after a single dose of Nitrosigine™. In addition, a significant increase in nitric oxide levels (measured as salivary nitrites) was seen after 14 days of product consumption (P<0.05). The results of the clinical study support the use of Nitrosigine™ as a bioavailable source of arginine and silicon, validating the preclinical studies and confirming Nitrosigine™ as an effective ingredient in products for sports nutrition, men’s health and cardiovascular health.
The clinical study verified Nitrosigine™ supplementation increased nitric oxide (NO) levels with a significant change in NO levels between the first treatment visit and after 14 days. The increase in NO levels can promote relaxation of smooth muscle in blood vessels, which increases blood flow and improves cardiovascular and muscular health.
Primary author, Douglas S. Kalman, PhD, RD, CCRC, FACN, Director BD, Nutrition & Applied Clinical Trials at Miami Research Associates stated, “Nitrosigine, a new FDA-approved arginine-based molecule, has early and preliminary research that is deserving of further development.”
Michael Satow, President and Chief Executive Officer of Nutrition 21 commented, “We are immensely pleased with the new clinical results, confirming our pre-clinical studies, and furthermore supporting Nitrosigine™’s ability to significantly increase nitric oxide levels to optimize the benefits of rigorous workouts. Fitness-focused customers who want to get the most out of their training regimen, will appreciate that Nitrosigine™ is quickly absorbed by the body, taking effect in 30 minutes and lasting up to three hours. Nitrosigine™ has also been shown to significantly raise arginine and silicon levels – both important nutrients for cardiovascular performance.”
Consumer benefits directly linked to the study findings include:
Nitrosigine™ significantly enhances nitric oxide levels
Nitrosigine™ is a safe, bioavailable source of arginine and silicon
Nitrosigine™ significantly increases plasma arginine levels in 30 minutes
Nitrosigine™ significantly increases plasma arginine levels for up to 3 hours
Nitrosigine™ significantly increases silicon levels for up to 1.5 hours
“Nutrition 21 is thrilled to have the human clinical study available as support for our NDI accepted, Nitrosigine™. Based on clinical and pre-clinical results, Nitrosigine™ demonstrates superiority over arginine as shown by increases in blood flow markers and silicon absorption. Nitrosigine™ is currently available in the retail channel in products such as, SuperPump® 3.0 and Razor8® and is in development in other finished goods. We anticipate continued high market interest with robust customer sales,” said Jim Kahn, Executive Director of National Sales at Nutrition 21.
About Experimental Biology 2014
The Experimental Biology (EB) meeting is a multi-society, interdisciplinary, biomedical, scientific meeting featuring plenary and award lectures, symposia, oral and poster sessions, a placement center, and an exhibit of scientific equipment, supplies, and publications. The meeting is one of the largest to date with over 14,000 attending scientists and researchers in the fields of anatomy, physiology, biochemistry, pathology, nutrition, and pharmacology. The Experimental Biology (EB) 2014 meeting will be held at the San Diego Convention Center, April 26 – 30, 2014.
For more information about the Experimental Biology 2014 annual meeting, please visit: http://www.experimentalbiology.org
About the Federation of American Societies for Experimental Biology (FASEB) Journal
The FASEB Journal is one of the world’s most cited biology journals. It is a preferred venue for the latest research reports and reviews of epigenetics, iRNA mechanics, histone acetylation, nitric oxide signaling, eicosanoid biochemistry, angiogenesis, tumor suppressor genes, apoptosis, cytoskeletal function, and human stem cell research. The journal publishes peer-reviewed, multidisciplinary original research articles, as well as editorials, reviews, and news of the life sciences.
For more information about the Federation of American Societies for Experimental Biology, please visit: http://www.FASEB.org
About Nutrition 21, LLC
Nutrition 21, a wholly owned subsidiary of JDS Therapeutics, is a leader in the nutritional supplement industry. The Company is a developer and marketer of efficacious, high-value, clinically substantiated ingredients for dietary supplements, medical foods and beverages, including CHROMAX® chromium picolinate and NITROSIGINE™ inositol-stabilized arginine silicate. In 2013 NITROSIGINE™ was accepted by the FDA as a New Dietary Ingredient (NDI).
With many years of biotechnology and pharmaceutical experience, the Company’s scientific platform has created unique, patentable products that are safe and clinically effective. Rigorous preclinical and clinical trials are a key part of its product development strategy to ensure product safety and consumer trust.
Nutrition 21 currently holds over 100 domestic and international issued and pending patents for products. Many support unique claims associated with, among others, glucose metabolism, weight management, brain health, cardiovascular health, and sports nutrition.
For more information, please visit: http://www.Nutrition21.com